Combating immunosuppression in glioma

Future Oncology

Volumn 4, Issue 3, 2008, Pages 433-442

  Vega, Eleanor A ^a   Graner, Michael W ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD25; CTLA 4; Cytotoxic T lymphocyte antigen 4; Foxp3; GITR; Glioblastoma multiforme; Glioma; Glucocorticoid induced tumor necrosis factor receptor related protein; Immunosuppression; Regulatory T cells; TGF ; Transforming growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 12009; BASILIXIMAB; BETAGLYCAN; CANCER VACCINE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACLIZUMAB; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOTOXIN LMB2; INTERLEUKIN 2; INTERLEUKIN 7; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; PROSTAGLANDIN E2; SD 208; SHORT HAIRPIN RNA; SMA 560; SX 007; TRANSCRIPTION FACTOR FOXP3 ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 KINASE INHIBITOR; UNINDEXED DRUG;

ADOPTIVE TRANSFER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; GLIOBLASTOMA; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; LYMPHOCYTOPENIA; MELANOMA; MONOTHERAPY; NEUROSURGERY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

BRAIN NEOPLASMS; GLIOMA; HUMANS; IMMUNOSUPPRESSION; T-LYMPHOCYTES, REGULATORY;

EID: 47249098938     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.3.433     Document Type: Review

References (79)

1. Stupp R, Mason WP, van den Bent MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
2. De Vleeschouwer S, van Gool SW, Van Calenbergh F: Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Childs Nerv. Syst. 21, 7-18 (2005).
3. Bechmann I, Galea I, Perry VH: What is the blood-brain barrier (not)? Trends Immunol. 28, 5-11 (2007).
4. Bechmann I, Priller J, Kovac A et al.: Immune surveillance of mouse brain perivascular spaces by blood-borne macrophages. Eur. J. Neurosci. 14, 1651-1658 (2001).
5. Poduslo JF, Ramakrishnan M, Holasek SS et al.: In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J. Neurochem. 102, 420-433 (2007).
6. Engelhardt B, Ransohoff RM: The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26, 485-495 (2005).
7. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC: CNS immune privilege: hiding in plain sight. Immunol. Rev. 213, 48-65 (2006).
8. Perry VH: A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J. Neuroimmunol. 90, 113-121 (1998).
9. Galea I, Bechmann I, Perry VH: What is immune privilege (not)? Trends Immunol. 28, 12-18 (2007).
10. Fecci PE, Mitchell DA, Whitesides JF et al.: Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66, 3294-3302 (2006).
11. Dix AR, Brooks WH, Roszman TL, Morford LA: Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunol. 100, 216-232 (1999).
12. Mahaley MS Jr, Brooks WH, Roszman TL, Bigner DD, Dudka L, Richardson S: Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J. Neurosurg. 46, 467-476 (1977).
13. Young HF, Sakalas R, Kaplan AM: Inhibition of cell-mediated immunity in patients with brain tumors. Surg. Neurol. 5, 19-23 (1976).
14. Brooks WH, Netsky MG, Normansell DE, Horwitz DA: Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med. 136, 1631-1647 (1972).
15. Elliott L, Brooks W, Roszman T: Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J. Natl Cancer Inst. 78, 919-922 (1987).
16. Ashkenazi E, Deutsch M, Tirosh R, Weinreb A, Tsukerman A, Brodie C: A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: increased level of soluble IL-2R and reduced protein tyrosine phosphorylation. Neuroimmunomodulation 4, 49-56 (1997).
17. Elliott LH, Brooks WH, Roszman TL: Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J. Clin. Invest. 86, 80-86 (1990).
18. Brooks WH, Rosman TL, Rogers AS: Impairment of rosette-forming T lymphoctyes in patients with primary intracranial tumors. Cancer 37, 1869-1873 (19-16).
19. Young HF, Kaplan AM: Cellular immune deficiency in patients with glioblastoma. Surg. Forum 27, 476-478 (1976).
20. Elliott L, Brooks W, Roszman T: Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation by dexamethasone, isoproterenol, or prostaglandin E2 either alone or in combination. Cell Mol. Neurobiol. 12, 411-427 (1992).
21. Roszman TL, Brooks WH: Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin. Exp. Immunol. 39, 395-402 (1980).
22. Roszman TL, Brooks WH, Elliott LH: Immunobiology of primary intracranial tumors. VI. Suppressor cell function and lectin-binding lymphocyte subpopulations in patients with cerebral tumors. Cancer 50, 1273-1279 (1982).
23. Huettner C, Czub S, Kerkau S, Roggendorf W, Tonn JC: Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res. 17, 3217-3224 (1997).
24. Brenner AV, Linet MS, Fine HA et al.: History of allergies and autoimmune diseases and risk of brain tumors in adults. Int. J. Cancer 99, 252-259 (2002).
25. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M: History of allergies among adults with glioma and controls. Int. J. Cancer 98, 609-615 (2002).
26. + T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J. Immunol. 171, 4927-4933 (2003).
27. Liau LM, Prins RM, Kiertscher SM et al.: Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11, 5515-5525 (2005).
28. + T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. 173, 4352-4439 (2004).
29. Fujita M, Zhu X, Sasaki K et al.: Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J. Immunol. 180, 2089-2098 (2008).
30. Parsa AT, Waldron JS, Panner A et al.: Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13, 84-88 (2007).
31. Massague J: TGF-β signal transduction. Annu. Rev. Biochem. 67, 753-791 (1998).
32. Platten M, Wick W, Weller M: Malignant glioma biology: role for TGF-β in growth, motility, angiogenesis, and immune escape. Microsc. Res. Tech. 52, 401-410 (2001).
33. Hunter KE, Sporn MB, Davies AM: Transforming growth factor-ß inhibit mitogen-stimulated proliferation of astrocytes. Glia 7, 203-211 (1993).
34. Rich JN, Zhang M, Datto MB, Bigner DD, Wang XF: Transforming growth factor-β-mediated p 15 (INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J. Biol. Chem. 274, 35053-35058 (1999).
35. Vergeli M, Mazzanti B, Ballerini C, Gran B, Amaducci L, Massacesi L: Transforming growth factor-β 1 inhibits the proliferation of rat astrocytes induced by serum and growth factors. J. Neurosci. Res. 40, 127-133 (1995).
36. Wesolowska A, Kwiatkowska A, Slomnicki L et al.: Microglia-derived TGF-β as an important regulator of glioblastoma invasion - an inhibition of TGF-β-dependent effects by shRNA against human TGF-β type II receptor. Oncogene 27(7), 918-930 (2007).
37. Paulus W, Baur I, Huettner C et al.: Effects of transforming growth factor-β 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J. Neuropathol. Exp. Neurol. 54, 236-244 (1995).
38. Koochekpour S, Merzak A, Pilkington GJ: Vascular endothelial growth factor production is stimulated by gangliosides and TGF-β isoforms in human glioma cells in vitro. Cancer Lett. 102, 209-215 (1996).
39. + regulatory T cells from human peripheral blood. J. Immunol. 166, 7282-7289 (2001).
40. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF: Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172, 5149-5153 (2004).
41. de Visser KE, Kast WM: Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia 13, 1188-1199 (1999).
42. Liu Y, Wang Q, Kleinschmidt-DeMasters BK, Franzusoff A, Ng KY, Lillehei KO: TGF-β2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. J. Neurooncol. 81, 149-162 (2007).
43. Hau P, Jachimczak P, Schlingensiepen R et al.: Inhibition of TGF-β2 with AP 12009 in recurrent malignant gliomas: from preclinical to Phase I/II studies. Oligonucleotides 17, 201-212 (2007).
44. Uhl M, Aulwurm S, Wischhusen J et al.: SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954-7961 (2004).
45. Tran TT, Uhl M, Ma JY et al.: Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol. 9, 259-270 (2007).
46. Wojtowicz-Praga S: Reversal of tumor-induced immunosuppression by TGF-β inhibitors. Invest. New Drugs 21, 21-32 (2003).
47. Dong M, How T, Kirkbride KC et al.: The type III TGF-β receptor suppresses breast cancer progression. J. Clin. Invest. 117, 206-217 (2007).
48. Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC: Loss of β-glycan expression in ovarian cancer: role in motility and invasion. Cancer Res. 67, 5231-5238 (2007).
49. Sharifi N, Hurt EM, Kawasaki BT, Farrar WL: TGFBR3 loss and consequences in prostate cancer. Prostate 67, 301-311 (2007).
50. Biswas S, Guix M, Rinehart C et al.: Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest. 117, 1305-1313 (2007).
51. Nam JS, Suchar AM, Kang MJ et al.: Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor β in a mouse model of breast cancer. Cancer Res. 66, 6327-6335 (2006).
52. + T regulatory cells: role of tumor-derived TGF-β. J. Immunol. 178, 2883-2892 (2007).
53. + regulatory T cells in tumor immunity. Curr. Top. Microbiol. Immunol. 293, 287-302 (2005).
54. + regulatory T cells and their therapeutic potential. Annu. Rev. Med. 57, 381-402 (2006).
55. Baecher-Allan C, Anderson DE: Regulatory cells and human cancer. Semin. Cancer Biol. 16, 98-105 (2006).
56. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287-296 (1998).
57. + immunoregulatory cells. J. Immunol. 167, 1137-1140 (2001).
58. + regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J. Exp. Med. 196, 247-253 (2002).
59. Liyanage UK, Moore TT, Joo HG et al.: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761 (2002).
60. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9, 4404-4408 (2003).
61. + T-regulatory cells. J. Immunother. (1997) 29, 313-319 (2006).
62. Fecci PE, Sweeney AE, Grossi PM et al.: Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin. Cancer Res. 12, 4294-4305 (2006).
63. + regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int. J. Cancer 121, 95-105 (2007).
64. Powell DJ Jr, Felipe-Silva A, Merino MJ et al.: Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J. Immunol. 179, 4919-4928 (2007).
65. + T cells. Cancer Immunol. Immunother. 57(1), 115-121 (2007).
66. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C: The IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 110(9), 3192-3201 (2007).
67. + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120, 2723-2733 (2007).
68. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA: Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28, 582-592 (2005).
69. Cranmer LD, Hersh E: The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 25, 613-631 (2007).
70. + T cell compartment without affecting regulatory T-cell function. Clin. Cancer Res. 13, 2158-2167 (2007).
71. Phan GQ, Yang JC, Sherry RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372-8377 (2003).
72. Attia P, Phan GQ, Maker AV et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043-6053 (2005).
73. Maker AV, Phan GQ, Attia P et al.: Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12, 1005-1016 (2005).
74. Nocentini G, Ronchetti S, Cuzzocrea S, Riccardi C: GITR/GITRL: more than an effector T cell co-stimulatory system. Eur. J. Immunol. 37, 1165-1169 (2007).
75. + regulatory T cells. J. Exp. Med. 202, 885-891 (2005).
76. + regulatory T cells. J. Leukoc. Biol. 82, 93-105 (2007).
77. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E: Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 67, 371-380 (2007).
78. Heimberger AB, Sun W, Hussain SF et al.: Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro. Oncol. 10, 98-103 (2008).
79. + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176, 1750-1758 (2006).